Formulation and evaluation of lipid based taste masked granules of ondansetron HCl

Kharb, Vandana; Saharan, Vikas Anand; Kharb, Vivek; Jadhav, Hemant R.; Purohit, Suresh

doi:10.1016/j.ejps.2014.05.012

Cited by 22 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glyceryl monostearate (GMS), a commonly used food emulsifier and thickener, has been used for taste-masking, for example, with ondansetron hydrochloride [ 55 ] and satranidazole [ 128 ] using a melt-quench process followed by sieving, with clarithromycin in combination with a polymer using spray congealing [ 26 ], and with praziquantel via spray drying and hot melt extrusion followed by milling and sieving to less than 400 μm [ 129 ]. For praziquantel, taste-masking performance was most effective with hot melt extrusion.…”

Section: Applications Of Twin-screw Melt Granulationmentioning

confidence: 99%

Twin-Screw Melt Granulation for Oral Solid Pharmaceutical Products

2021

View full text Add to dashboard Cite

This article highlights the advantages of pharmaceutical continuous melt granulation by twin-screw extrusion. The different melt granulation process options and excipients are described and compared, and a case is made for expanded use of twin-screw melt granulation since it is a flexible and continuous process. Methods for binder selection are profiled with a focus on rheology and physical stability impacts. For twin-screw melt granulation, the mechanism of granulation and process impact on granule properties are described. Pharmaceutical applications of melt granulation ranging from immediate release of soluble and insoluble APIs, taste-masking, and sustained release formulation are reviewed, demonstrating the range of possibilities afforded by twin-screw melt granulation.

show abstract

Section: Applications Of Twin-screw Melt Granulationmentioning

confidence: 99%

Twin-Screw Melt Granulation for Oral Solid Pharmaceutical Products

2021

View full text Add to dashboard Cite

show abstract

“…6) Physical bitterness masking is a masking technique by controlling the release of bitter-tasting active ingredients. 7,8,9) Chemical masking is a masking technology that suppresses bitterness using chemical factors such as chemical modification of bitter-tasting active ingredients. 10) Solid dispersion, introduced by Sekiguchi and Obi (1961), 11) defined as "the dispersion of one or more active ingredients in an inert matrix at solid-state prepared by melting (fusion), solvent or melting-solvent methods" by Chiou and Riegelman (1971).…”

Section: Introductionmentioning

confidence: 99%

Development of Ethylcellulose Microparticles for Taste Masking of Fexofenadine

Ikeuchi-Takahashi,

Morii,

Yamazaki

et al. 2024

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

For taste masking of fexofenadine hydrochloride (FXD), ethylcellulose (EC) microparticles with FXD were developed. The amounts of EC, Tween 80, and polyvinyl alcohol (PVA) in the composition had little effect on initial drug release properties. Based on the results of the drug recovery and the drug release properties, FXD(EC200) was the optimal FXD microparticle formulation. From the results of Fourier transform infrared spectroscopy spectra and X-ray diffraction patterns of FXD(EC200), FXD amorphization in the microparticles and interaction between FXD and other components were suggested, and the formation of a solid dispersion of FXD was suggested. Because the possibility of the complex of PVA and FXD on the particle surface was suggested, sodium lauryl sulfate (SLS) was added to the composition. The initial drug release from FXD microparticles with SLS was further suppressed compared with FXD(EC200). From these results, FXD microparticles with SLS can be prepared as a controlled-release formulation and are expected to be useful for masking the bitter tasting particulates.

show abstract

“…Published studies have shown that formoterol fumarate has a rapid bronchiectasis effect [ 16 ], which may enhance compliance, and continue bronchiectasis within 12 hours, with a cumulative effect when inhaled twice a day. Ambroxol hydrochloride tablets are mainly suitable for patients with thick sputum that is not easy to cough up [ 17 ]. Studies have shown that after treatment with ambroxol hydrochloride tablets, the number of inflammatory cells and plasma TNF- α , IL-8, and IL-6 levels in COPD rats were significantly reduced after treatment, and lung tissue inflammation was reduced [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease

Zhang²,

Yan

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide. However, there are few studies of tiotropium bromide on sputum and sputum viscosity. To evaluate the effect of tiotropium bromide on mucus hypersecretion, a randomized, double-blind controlled trial was performed. Methods. 120 cases of patients with pulmonary function grade II were divided into two groups, which include the treatment group given tiotropium bromide powder inhalation (18 μg, inhalation, QD) and the control group given formoterol fumarate powder inhalation (12 μg, inhalation, BID) plus ambroxol hydrochloride tablets (60 mg, oral, TID). After 3 months of treatment, the pulmonary function and α1-acid glycoprotein (α1-AGP) in sputum were detected, and the changes of glycoprotein and Ca2+ content were evaluated by Miller classification. Results. Three patients (2 cases in the treatment group and 1 case in the control group) were dropped due to loss of follow-up, and 117 cases of patients were enrolled in this study. After 3 months of treatment, the sputum character score, α1-acid glycoprotein, Ca2+ content, and lung function of the two groups were significantly improved; group comparison analyses revealed that there was no significant difference in the content of α1-AGP, Ca2+ in sputum, and lung function between the two groups ( P > 0.05 ), but the improvement of sputum properties was significant ( P < 0.05 ), and the treatment group was better than the control group ( t = − 2.77 ; P = 0.007 ). Conclusions. Inhaled tiotropium bromide can effectively inhibit the mucus hypersecretion in stable COPD patients, improve the sputum properties and lung function of patients, and improve the quality of life of patients.

show abstract

Formulation and evaluation of lipid based taste masked granules of ondansetron HCl

Cited by 22 publications

References 39 publications

Twin-Screw Melt Granulation for Oral Solid Pharmaceutical Products

Twin-Screw Melt Granulation for Oral Solid Pharmaceutical Products

Development of Ethylcellulose Microparticles for Taste Masking of Fexofenadine

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About